Kanuma
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Sebelipase alfa
- Made by
- Alexion Europe SAS
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Alexion Europe SAS |
|---|---|
| Active substance | Sebelipase alfa |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A16 · Digestion, stomach, diabetes and nutrition |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2015-08-28 |
| Last updated by the regulator | 2026-03-24 |
| EMA product number | EMEA/H/C/004004 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).